Literature DB >> 7984506

Molecular forms of circulating atrial natriuretic peptides in human plasma and their metabolites.

W R Gower1, S Chiou, K A Skolnick, D L Vesely.   

Abstract

High performance gel permeation chromatography (HP-GPC) followed by four radioimmunoassays (RIAs) devised to amino acids (a.a.) 1-30, 31-67, 79-98, and 99-126 of the 126 a.a. atrial natriuretic factor (ANF) prohormone revealed that the proANF(1-30) assay immunoreactivity in plasma is 50% proANF(1-30) and 50% proANF(1-98). The HP-GPC evaluation of plasma followed by proANF(31-67) and ANF [i.e., proANF(99-126)] assays revealed that proANF(31-67) and ANF circulate as distinct peptides. the HP-GPC plasma examination followed by proANF(79-98) assay immunologically recognized three peaks in plasma consistent with proANF(1-98), -(68-98), and -(79-98). Similar HP-GPC evaluation of urine followed by these RIAs indicated that the proANF(1-30), -(79-98), and ANF assays only recognize 500 mol.wt. or less peptides, and the proANF(31-67) RIA recognizes a nearly intact proANF(31-67) with only two to three amino acids removed during processing of this peptide.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7984506     DOI: 10.1016/0196-9781(94)90043-4

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  3 in total

1.  Clinical relevance of cardiac natriuretic peptides measured by means of competitive and non-competitive immunoassay methods in patients with renal failure on chronic hemodialysis.

Authors:  A Clerico; R Caprioli; S Del Ry; D Giannessi
Journal:  J Endocrinol Invest       Date:  2001-01       Impact factor: 4.256

Review 2.  Molecular forms of natriuretic peptides in heart failure and their implications.

Authors:  Ye Olivia Xu-Cai; Qingyu Wu
Journal:  Heart       Date:  2009-05-17       Impact factor: 5.994

Review 3.  Atrial Natriuretic Peptide31-67: A Novel Therapeutic Factor for Cardiovascular Diseases.

Authors:  Gustavo Jose Justo da Silva; Raffaele Altara; George W Booz; Alessandro Cataliotti
Journal:  Front Physiol       Date:  2021-07-08       Impact factor: 4.566

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.